Diagnocure, Inc.
Diagnocure, Inc. (DGCRF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
dgcrf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Specialties · 3 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Diagnocure, Inc.You DGCRF | $0M | N/A | — | — |
 Humanigen, Inc. HGENQ | $0M | N/A | — | — |
 NutraLife BioSciences, Inc. NLBS | $0M | N/A | — | -$0.04 |
 NMC Health plc NMMCF | $0M | 30.10x | — | $1.20 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Diagnocure, Inc. (DGCRF) measures how much investors pay for each dollar of the company's trailing earnings. DGCRF's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
DGCRF pe ratio · 6 questionsDGCRF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via DGCRF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Diagnocure, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09